Skip to main content

Table 1 Demographic and clinical features

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

Age32 years (17–60)
Age of onset18 years (3–46)
Sex
 Femalen: 3249.2%
 Malen: 3350.8%
Duration of usen: 65 (100%)7 month (3–30)
 Anakinran: 41 (63.1%)6 month (3–30)
 Canakinumabn: 24 (39.6%)8 month (3–25)
Clinical Features
 Fevern: 6092.5%
 Peritonitisn: 6193.8%
 Erysipales LEn: 1827.7%
 Amlyloidosisn: 1523.1%
 Arthritisn: 1116.9%
 Pleuritisn: 2030.8%
 AxSpan: 913.8%
 Renal transn: 710.8%
MEFV Mutation
 M694 V homozygousn: 2944.6%
 M694 V heterozygousn: 812.3%
 M680I homozygousn: 46.2%
 E148Q homozygousn: 11.5%
 Compoundn: 1624.6%
 Non: 34.6%
 R761H heterozygousn: 11.5%
 Othersn: 34.6%
Indications of Anti-IL1 therapy
 Colchicine-Intolerantn: 812.3%
 Colchicine-Resistantn: 4670.8%
 Proteinurian: 1523.1%
  1. All parameters are presented as median (min–max) or number (%). LE like erythema, AxSpa axialspondyloarthropathy